Johnson & Johnson Adicet Bio, Inc. Transaction History
Johnson & Johnson
- $475 Million
- Q1 2024
A detailed history of Johnson & Johnson transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Johnson & Johnson holds 364,472 shares of ACET stock, worth $441,011. This represents 0.18% of its overall portfolio holdings.
Number of Shares
364,472
Previous 728,944
50.0%
Holding current value
$441,011
Previous $998,000
14.23%
% of portfolio
0.18%
Previous 0.39%
Shares
2 transactions
Others Institutions Holding ACET
# of Institutions
107Shares Held
69.5MCall Options Held
13.3KPut Options Held
24.6K-
Orbimed Advisors LLC San Diego, CA11.4MShares$13.9 Million0.61% of portfolio
-
Tang Capital Management LLC San Diego, CA6.41MShares$7.75 Million1.83% of portfolio
-
Balyasny Asset Management LLC Chicago, IL6.18MShares$7.48 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY4.13MShares$5 Million0.16% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.11MShares$4.97 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $48.4M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...